Sunita Gulati to Gonorrhea
This is a "connection" page, showing publications Sunita Gulati has written about Gonorrhea.
Connection Strength
6.437
-
Gulati S, Mattsson AH, Schussek S, Zheng B, DeOliveira RB, Shaughnessy J, Lewis LA, Rice PA, Comstedt P, Ram S. Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence. mBio. 2023 Dec 19; 14(6):e0250023.
Score: 0.746
-
Gulati S, Schoenhofen IC, Lindhout-Djukic T, Lewis LA, Moustafa IY, Saha S, Zheng B, Nowak N, Rice PA, Varki A, Ram S. Efficacy of Antigonococcal CMP-Nonulosonate Therapeutics Require Cathelicidins. J Infect Dis. 2020 10 13; 222(10):1641-1650.
Score: 0.604
-
Gulati S, Schoenhofen IC, Lindhout-Djukic T, Schur MJ, Landig CS, Saha S, Deng L, Lewis LA, Zheng B, Varki A, Ram S. Therapeutic CMP-Nonulosonates against Multidrug-Resistant Neisseria gonorrhoeae. J Immunol. 2020 06 15; 204(12):3283-3295.
Score: 0.587
-
Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 2019 06; 17(6):e3000323.
Score: 0.551
-
Gulati S, Rice PA, Ram S. Complement-Dependent Serum Bactericidal Assays for Neisseria gonorrhoeae. Methods Mol Biol. 2019; 1997:267-280.
Score: 0.534
-
Gulati S, Schoenhofen IC, Whitfield DM, Cox AD, Li J, St Michael F, Vinogradov EV, Stupak J, Zheng B, Ohnishi M, Unemo M, Lewis LA, Taylor RE, Landig CS, Diaz S, Reed GW, Varki A, Rice PA, Ram S. Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics. PLoS Pathog. 2015 Dec; 11(12):e1005290.
Score: 0.431
-
Gulati S, Mu X, Zheng B, Reed GW, Ram S, Rice PA. Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model. J Infect Dis. 2015 Jul 15; 212(2):311-5.
Score: 0.406
-
Gulati S, Zheng B, Reed GW, Su X, Cox AD, St Michael F, Stupak J, Lewis LA, Ram S, Rice PA. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog. 2013; 9(8):e1003559.
Score: 0.369
-
Su X, Le W, Zhu X, Li S, Wang B, Madico G, Yang Z, Chaisson CE, McLaughlin RE, Gandra S, Yoon J, Zheng B, Lewis LA, Gulati S, Reed GW, Ram S, Rice PA. Neisseria gonorrhoeae Infection in Women Increases With Rising Gonococcal Burdens in Partners: Chlamydia Coinfection in Women Increases Gonococcal Burden. J Infect Dis. 2022 12 13; 226(12):2192-2203.
Score: 0.175
-
Shaughnessy J, Chabeda A, Tran Y, Zheng B, Nowak N, Steffens C, DeOliveira RB, Gulati S, Lewis LA, Maclean J, Moss JA, Wycoff KL, Ram S. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 2022; 13:975676.
Score: 0.172
-
Lewis LA, Gulati S, Zelek WM, Morgan BP, Song WC, Zheng B, Nowak N, DeOliveira RB, Sanchez B, DeSouza Silva L, Schuurman J, Beurskens F, Ram S, Rice PA. Efficacy of an Experimental Gonococcal Lipooligosaccharide Mimitope Vaccine Requires Terminal Complement. J Infect Dis. 2022 05 16; 225(10):1861-1864.
Score: 0.169
-
Parzych EM, Gulati S, Zheng B, Bah MA, Elliott STC, Chu JD, Nowak N, Reed GW, Beurskens FJ, Schuurman J, Rice PA, Weiner DB, Ram S. Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection. mBio. 2021 03 16; 12(2).
Score: 0.155
-
Chakraborti S, Gulati S, Zheng B, Beurskens FJ, Schuurman J, Rice PA, Ram S. Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7. Infect Immun. 2020 01 22; 88(2).
Score: 0.144
-
Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, M?rgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019 12 05; 4(23).
Score: 0.142
-
Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, DeOliveira RB, Shaughnessy J, Reed GW, Ram S, Rice PA. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine. mBio. 2019 11 05; 10(6).
Score: 0.141
-
Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol. 2019; 10:321.
Score: 0.135
-
Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, DeOliveira RB, Gose S, Reed GW, Botto M, Rice PA, Ram S. Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae. J Immunol. 2018 11 01; 201(9):2700-2709.
Score: 0.131
-
Ram S, Gulati S, Lewis LA, Chakraborti S, Zheng B, DeOliveira RB, Reed GW, Cox AD, Li J, St Michael F, Stupak J, Su XH, Saha S, Landig CS, Varki A, Rice PA. A Novel Sialylation Site on Neisseria gonorrhoeae Lipooligosaccharide Links Heptose II Lactose Expression with Pathogenicity. Infect Immun. 2018 08; 86(8).
Score: 0.129
-
Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis. 2017 06 01; 75(4).
Score: 0.120
-
Ketterer MR, Rice PA, Gulati S, Kiel S, Byerly L, Fortenberry JD, Soper DE, Apicella MA. Desialylation of Neisseria gonorrhoeae Lipooligosaccharide by Cervicovaginal Microbiome Sialidases: The Potential for Enhancing Infectivity in Men. J Infect Dis. 2016 Dec 01; 214(11):1621-1628.
Score: 0.113
-
Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016 Feb 15; 196(4):1732-40.
Score: 0.109
-
Lewis LA, Gulati S, Burrowes E, Zheng B, Ram S, Rice PA. a-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tract. mBio. 2015 Feb 03; 6(1).
Score: 0.102
-
Ngampasutadol J, Tran C, Gulati S, Blom AM, Jerse EA, Ram S, Rice PA. Species-specificity of Neisseria gonorrhoeae infection: do human complement regulators contribute? Vaccine. 2008 Dec 30; 26 Suppl 8:I62-6.
Score: 0.067
-
Ngampasutadol J, Ram S, Blom AM, Jarva H, Jerse AE, Lien E, Goguen J, Gulati S, Rice PA. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A. 2005 Nov 22; 102(47):17142-7.
Score: 0.054
-
Porter E, Yang H, Yavagal S, Preza GC, Murillo O, Lima H, Greene S, Mahoozi L, Klein-Patel M, Diamond G, Gulati S, Ganz T, Rice PA, Quayle AJ. Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun. 2005 Aug; 73(8):4823-33.
Score: 0.053
-
Bash MC, Zhu P, Gulati S, McKnew D, Rice PA, Lynn F. por Variable-region typing by DNA probe hybridization is broadly applicable to epidemiologic studies of Neisseria gonorrhoeae. J Clin Microbiol. 2005 Apr; 43(4):1522-30.
Score: 0.051
-
Shaughnessy J, Tran Y, Zheng B, DeOliveira RB, Gulati S, Song WC, Maclean JM, Wycoff KL, Ram S. Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front Immunol. 2020; 11:583305.
Score: 0.038
-
Banerjee A, Wang R, Supernavage SL, Ghosh SK, Parker J, Ganesh NF, Wang PG, Gulati S, Rice PA. Implications of phase variation of a gene (pgtA) encoding a pilin galactosyl transferase in gonococcal pathogenesis. J Exp Med. 2002 Jul 15; 196(2):147-62.
Score: 0.011